The Science
See how clinicians assess fit, use baseline and follow-up labs when clinically indicated, monitor care, interpret incomplete evidence and distinguish FDA approval from advisory review and lawful compounding pathways.
Care comes first
Published research informs care; it does not decide care. Clinical judgment helps apply the available evidence to one patient and does not replace missing evidence. Laboratory results are reviewed when they can meaningfully assess baseline risk, response or safety, not as a one-size-fits-all testing schedule.
A licensed clinician reviews health history, current medications, contraindications, goals and jurisdiction-specific requirements before deciding whether to prescribe.
If treatment is appropriate, the clinician selects the preparation and starting plan. Any escalation occurs only when prescribed and clinically appropriate.
The care team coordinates check-ins, response and adverse-effect review, plus baseline or follow-up laboratory monitoring when clinically indicated. Results can inform whether the plan is continued, adjusted or stopped.
Regulatory context
Status summary reviewed September 19, 2026. Rules and availability can change; a clinician and dispensing pharmacy confirm the current pathway for each prescription.
FDA approval means the agency evaluated a specific drug for safety, effectiveness and manufacturing quality for its approved use. Compounded drugs are not FDA-approved.
An advisory-committee discussion or recommendation informs the FDA; it is not itself a final agency decision, approval or authorization to market a product.
Sections 503A and 503B describe different federal conditions for compounding. Whether a preparation may be compounded and dispensed depends on the substance, prescription, pharmacy, patient, timing and applicable federal and state law.
BPC-157 and TB-500: human clinical evidence is limited, product and compounding status may evolve, and neither an advisory recommendation nor preclinical research is a final FDA decision or proof that a therapy safely treats any disease. Pacific RX does not present either peptide as a proven treatment for ulcerative colitis or another disease. Access is never guaranteed and depends on a clinician’s decision, pharmacy acceptance and current law.
BPC-157 · Safety review
A best practice advisory (BPA) is a clinical-system alert. Its absence is not safety clearance. BPC-157 has no FDA-approved prescribing label defining contraindications, interactions or a validated dosing regimen. Limited human evidence means these risks are incompletely characterized, rather than absent.
Tell the clinician about pregnancy or breastfeeding, allergies and prior reactions, all medications and supplements, and significant medical conditions. A registered BPC-157 trial excludes pregnancy, breastfeeding, ingredient hypersensitivity and significant uncontrolled illness. Trial exclusions are precautions, not a validated clinical contraindication list.
The registered trial also excludes known bleeding disorders, therapeutic anticoagulation and recent use of systemic corticosteroids, anabolic agents or investigational peptides. These study criteria inform questions for a clinician; they do not establish which combinations are safe outside the trial.
Ask about established care options, unresolved interaction risks and what symptoms would require stopping and seeking care. Do not start or adjust BPC-157 based on an absent alert or a research dosing example.
Ongoing work · reviewed October 14, 2026
Trial phase describes development stage, not approval or certainty of benefit. Status reflects the linked source at review; recruitment and study timelines can change.
Tags describe the named therapy and use at the review date, not the age or design of a cited paper. Development can stop or change; phase 3 results do not imply an application is submitted or under FDA review. Designations support development and are separate from approval. Approval applies to a specific product and indication, not to compounded preparations. General care articles may cover multiple stages and have no single therapy tag.
A phase 2 hamstring registration lists recruiting; a phase 1 rotator cuff study is not yet recruiting. Neither has posted results. BPC-157 has no established clinical dose or validated titration schedule.
The small IV pilot used 10 mg followed by 20 mg the next day in two adults. Those exposures cannot be translated into a recovery protocol or subcutaneous dosing guidance.
Retatrutide targets GIP, GLP-1 and glucagon receptors. Phase 3 TRIUMPH-1 results are reported, with further studies examining maintenance and other outcomes. It remains investigational.
Previously studied weekly targets: phase 2 used 1, 4, 8 and 12 mg; TRIUMPH-1 used 4, 9 and 12 mg. In TRIUMPH-1, participants began at 2 mg weekly and advanced every four weeks through intermediate steps to their assigned target. These are research regimens, not prescribing instructions.
For incretin care, discuss weight and metabolic goals, current walking or exercise, strength and daily function, nutrition, prior medication doses and tolerability with your clinician. Prior exposure helps frame a review; it does not establish an equivalent dose when switching medications.
Build activity from your current baseline. General adult guidance aims for at least 150 minutes of moderate activity weekly and muscle-strengthening activity on two days, adapted to health and mobility. Track progress alongside symptoms and treatment response.
NIH activity and goal guidanceEvidence standard
This page is built for physician review and verification: human trial evidence first, preclinical evidence clearly labeled. Every study card links out to the published record.
47
linked publications
7
therapy areas
2
evidence categories
Randomized trials and long-term outcome studies carry the most weight when a protocol has direct clinical data.
Animal or in vitro findings are labeled as preclinical and are not presented as proven human benefits.
Biological rationale
Peptides are short chains of amino acids that relay precise instructions between cells and tissues, forming an essential part of how the body's physiology functions.
When a compounded preparation is prescribed, a clinician documents why it is appropriate for the individual patient and routes the prescription to an eligible U.S. pharmacy partner.
Protocols draw on peer-reviewed endocrinology, regenerative-medicine and human physiology literature, then narrow decisions through physician review.
Published studies
These are not marketing claims. They are starting points for physician review, therapeutic regimen selection and risk discussion. When human trials exist, they are listed before supporting review or preclinical literature, and suggested starting studies sit at the top of each list.
Metabolic care
Human randomized trials anchor the metabolic program. The structure starts with direct weight-loss endpoints, then separates diabetes, established disease-specific outcomes and investigational impacts so patients and clinicians can compare like with like.
Diabetes-specific endpoints
New England Journal of Medicine, 2016
SUSTAIN-6 cardiovascular safety and outcomes trial in type 2 diabetes.
Repair and recovery
This category is mostly preclinical. We surface that distinction clearly because animal and cell data are not the same as human outcome trials. Repair protocols are also prescribed alongside graded exercise or rehabilitation of the affected area, because improving blood flow to the healing tissue is part of the therapeutic rationale.
Metabolic cofactor
NAD+ is a metabolic cofactor essential to cellular energetics. This section presents biochemical and early human physiology literature, not proof of a defined disease-treatment, disease-prevention, metabolic-health or longevity endpoint.
Peptide immunology
These papers are not treatment claims for Pacific RX protocols. They show how peptide-based signaling can be investigated in rigorous human immunology and oncology settings, including combination strategies with immunotherapy.
Endocrine body composition
Growth-hormone-axis protocols draw from specific endocrine trials and are narrowed through physician review of symptoms, risks, goals and monitoring needs.
Sexual wellness
Sexual-wellness protocols require careful evaluation of regimen fit. The evidence here is strongest for bremelanotide in premenopausal women with acquired generalized HSDD.
Hormone care
Hormone protocols are evaluated around symptoms, labs, route, age, risk factors and follow-up. These papers highlight both potential benefit and the need for individualized prescribing.
Clinical translation
What the literature can do
It defines biological rationale, expected benefit, known adverse effects, contraindications and monitoring requirements.
What your clinician still decides
Whether a therapy fits your history, labs, medications, goals and state-specific prescribing requirements.
How dosing is approached
The prescribing clinician selects the starting plan. Dose changes are considered only after reviewing response, tolerability and relevant clinical information, and only when prescribed and clinically appropriate.
What makes results interpretable
Expectations are benchmarked against a realistic timeline, and medications are paired with diet, exercise or tissue-specific rehabilitation where that is part of the therapeutic rationale.
What the premium supports
Pacific RX pricing reflects access to credentialed clinicians, individualized review, coordinated monitoring, vetted fulfillment relationships, clinical documentation and ongoing support. A higher price does not mean a compounded product is FDA-approved, proven superior, risk-free or equivalent to an approved drug.
A careful note
Some therapies have large human trials; others have mainly biology-focused, preclinical or review literature. Pacific RX presents this page as education, not a guarantee of treatment, outcome or prescription.
Browse protocolsRetatrutide articles
Retatrutide is investigational. These articles are included for education and clinical context, not as a guarantee of access, approval or prescribing.
New England Journal of Medicine, 2023
Nature Medicine, 2024
Nature Medicine, 2023
Start with the protocol overview, then complete intake when you are ready for a clinician to review your history.
Browse protocols